DRIL Presence Predictive of VA Improvement in Patients with Macular Edema, RVO
Amy S. Babicuh, MD, noted that “while DRIL is not the biomarker, it is certainly useful in conjunction with other information, and should prompt continued treatment with anti-VEGF agents when it is present.”
Diabetic Retinopathy Telemedicine Screening Could Greatly Benefit Underserved Populations
July 23rd 2018Telemedicine screenings provided by a primary care office in an urbanized setting over 2 years showed patients had an 81.9% compliance capture rate—a significant improvement from previous studies in the same field.
Real-World Analysis Supports More Frequent Anti-VEGF Dosing for First-Year nAMD
July 21st 2018Researchers found that, contrary to popular opinion, about 80% of patients are receiving at least 7 dosing regimens of anti-VEGF in their first year of treatment, and that frequency has been proven to improve visual acuity.